Natera (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 317 Shares

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 317 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $267.99, for a total value of $84,952.83. Following the sale, the chief financial officer owned 52,115 shares of the company’s stock, valued at approximately $13,966,298.85. This represents a 0.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, August 4th, Michael Burkes Brophy sold 478 shares of Natera stock. The stock was sold at an average price of $274.22, for a total value of $131,077.16.
• On Wednesday, July 29th, Michael Burkes Brophy sold 1,863 shares of Natera stock. The stock was sold at an average price of $249.38, for a total value of $464,594.94.
• On Tuesday, July 28th, Michael Burkes Brophy sold 2,419 shares of Natera stock. The stock was sold at an average price of $253.96, for a total value of $614,329.24.
• On Monday, July 27th, Michael Burkes Brophy sold 782 shares of Natera stock. The shares were sold at an average price of $260.49, for a total value of $203,703.18.

Natera Price Performance

NTRA opened at $274.58 on Thursday. The business has a fifty day simple moving average of $251.03 and a 200 day simple moving average of $222.85. Natera, Inc. has a 1 year low of $135.75 and a 1 year high of $288.04. The company has a market capitalization of $39.32 billion, a PE ratio of -168.45 and a beta of 1.51.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Canaccord Genuity Group upped their price target on shares of Natera from $285.00 to $330.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Wolfe Research began coverage on shares of Natera in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price objective for the company. Sanford C. Bernstein started coverage on shares of Natera in a report on Friday, June 26th. They issued an “outperform” rating and a $310.00 price objective for the company. Morgan Stanley increased their target price on shares of Natera from $250.00 to $310.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Finally, JPMorgan Chase & Co. raised their target price on shares of Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $267.83.

Institutional Trading of Natera

Several large investors have recently modified their holdings of NTRA. Robinhood Asset Management LLC bought a new stake in shares of Natera during the fourth quarter worth $12,981,000. UBS Group AG lifted its stake in shares of Natera by 19.4% in the 4th quarter. UBS Group AG now owns 438,857 shares of the medical research company’s stock valued at $100,538,000 after acquiring an additional 71,355 shares during the last quarter. ABN Amro Investment Solutions lifted its stake in shares of Natera by 44.6% in the 1st quarter. ABN Amro Investment Solutions now owns 9,346 shares of the medical research company’s stock valued at $1,869,000 after acquiring an additional 2,883 shares during the last quarter. Fifth Third Bancorp boosted its holdings in shares of Natera by 3,373.1% during the 1st quarter. Fifth Third Bancorp now owns 11,253 shares of the medical research company’s stock valued at $2,251,000 after acquiring an additional 10,929 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its holdings in shares of Natera by 286.8% during the 4th quarter. Teacher Retirement System of Texas now owns 65,717 shares of the medical research company’s stock valued at $15,055,000 after acquiring an additional 48,728 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera filed with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for approval of its Signatera test for bladder cancer. Approval would expand the addressable market for the company’s molecular residual disease testing and could support additional international revenue growth. Natera Files for Japan PMDA Approval of Signatera Test in Bladder Cancer
• Neutral Sentiment: Natera reported sales by CEO Steven Leonard Chapman, CFO Michael Burkes Brophy, and executives Solomon Moshkevich and John Fesko totaling approximately 7,576 shares and $2.02 million. Each sale was executed under a pre-arranged Rule 10b5-1 plan and was made to cover tax withholding obligations from vested equity awards. The executives retained substantial positions, reducing the significance of the transactions as a signal of weakening confidence.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.